Who owns Cellectar Biosciences, Inc.?
- Ticker: CLRB
- CUSIP Number: 15117f807
Tip: Access positions for across all investors
Analyze quarterly positions in Cellectar Biosciences with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Cellectar Biosciences stock
Who bought or sold Cellectar Biosciences, Inc. this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| AIGH Capital Management | 2.8M | $11M | 46% | Mar 2024 |
|
| Nantahala Capital Management | 1.9M | $7.5M | 39% | Mar 2024 |
|
| Vanguard Group | 1.2M | $4.7M | 147% | Mar 2024 |
|
| ADAR1 Capital Management | 643k | $2.6M | -53% | Mar 2024 |
|
| Rosalind Advisors | 622k | $2.5M | -69% | Mar 2024 |
|
| Barclays | 338k | $1.3M | 100% | Mar 2024 |
|
| Geode Capital Management | 316k | $1.3M | 403% | Mar 2024 |
|
| Citadel Advisors | 187k | $743k | 171% | Mar 2024 |
|
| Hudson Bay Capital Management | 150k | $597k | 100% | Mar 2024 |
|
| BlackRock | 142k | $567k | 150% | Mar 2024 |
|
| Lighthouse Investment Partners | 139k | $552k | 100% | Mar 2024 |
|
| Jane Street | 59k | $237k | 100% | Mar 2024 |
|
| Northern Trust | 52k | $208k | 100% | Mar 2024 |
|
| Susquehanna International | 46k | $183k | 100% | Mar 2024 |
|
| Goss Wealth Management | 45k | $178k | 100% | Mar 2024 |
|
| Raymond James & Associates | 36k | $143k | 100% | Mar 2024 |
|
| Raymond James Financial Services Advisors | 30k | $119k | 100% | Mar 2024 |
|
| Belvedere Trading | 29k | $117k | 100% | Mar 2024 |
|
| Morgan Stanley | 21k | $85k | 42% | Mar 2024 |
|
| Two Sigma Investments | 20k | $81k | 100% | Mar 2024 |
|
| Integrated Wealth Concepts | 20k | $80k | 100% | Mar 2024 |
|
| Bank of America Corporation | 19k | $77k | 121112% | Mar 2024 |
|
| Squarepoint Ops | 18k | $72k | 100% | Mar 2024 |
|
| LLBH Private Wealth Management | 16k | $64k | -30% | Mar 2024 |
|
| Commerce Bank N A | 16k | $64k | 33% | Mar 2024 |
|
| Two Sigma Advisers | 13k | $53k | 100% | Mar 2024 |
|
| XTX Topco | 12k | $47k | 100% | Mar 2024 |
|
| Group One Trading | 8.0k | $32k | 100% | Mar 2024 |
|
| UBS Group | 6.0k | $24k | 396% | Mar 2024 |
|
| Tower Research Capital | 5.4k | $22k | -9% | Mar 2024 |
|
| Simplex Trading | 3.7k | $14k | 100% | Mar 2024 |
|
| Royal Bank of Canada | 2.5k | $10k | 100% | Mar 2024 |
|
| BFSG | 1.0k | $4.0k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 521.00 | $2.1k | 0% | Mar 2024 |
|
| ICA Group Wealth Management | 350.00 | $1.4k | 100% | Mar 2024 |
|
| Pnc Financial Services | 300.00 | $1.2k | 100% | Mar 2024 |
|
| Us Bancorp | 285.00 | $1.1k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 205.00 | $816.002500 | 242% | Mar 2024 |
|
| EnRich Financial Partners | 102.00 | $406.000800 | 100% | Mar 2024 |
|
| Harbour Investments | 40.00 | $111.000000 | 0% | Dec 2023 |
|
| AllSquare Wealth Management | 18.00 | $72.000000 | 0% | Mar 2024 |
|
Who sold out of Cellectar Biosciences?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Worth Venture Partners | Dec 2023 | 694k | $1.9M |
| FMR | Sep 2023 | 48.00 | $126.998400 |
| Jpmorgan Chase & Co | Dec 2023 | 20.00 | $55.000000 |